PV Solutions Expert Invited to Boao Real-World Research Conference 2026
PV Solutions expert Sherley Wang has been invited to the 5th Boao International Drug and Medical Device Real-World Research Conference, focusing on pharmacovigilance, real-world data and regulatory science.
PV Solutions Expert Invited to the 5th Boao International Drug and Medical Device Real-World Research Conference
PV Solutions Limited is pleased to announce that Ms. Sherley (Wang Xueling), an expert on our team, has been invited to organize in the 5th Boao International Drug and Medical Device Real-World Research Conference, to be held in Boao, Hainan, China, from 20–22 November 2026.
The invitation was issued by the organizing committee of the Boao International Drug and Medical Device Real-World Research Conference, with support from China's regulatory authorities.
The conference will bring together representatives from regulatory authorities, international organizations, research institutions, pharmaceutical companies and other stakeholders to exchange experience and research findings related to real-world data, real-world research, drug and medical device evaluation, regulatory science, and pharmaceutical innovation.
For PV Solutions Limited, participation in this event represents an important opportunity to engage with China's evolving regulatory and scientific environment and to exchange perspectives with experts across the pharmaceutical and life sciences sectors.
A Conference Focused on Real-World Data and Regulatory Science
According to the invitation, the 5th Boao International Drug and Medical Device Real-World Research Conferencewill take place from 20 to 22 November 2026 in Boao, Hainan.
The conference theme focuses on:
Real-World Data Enabling High-Quality Development of the Pharmaceutical Industry
The programme includes a main conference, thematic forums and dedicated sessions covering areas across the pharmaceutical and medical device lifecycle.
Key areas include:
Drug and medical device real-world research
Real-world data applications
Regulatory science
Clinical evaluation
Drug safety and pharmacovigilance
Post-market risk management
Regulatory and scientific innovation
International regulatory experience and exchange
The event is expected to provide a platform for discussion between regulatory authorities, industry professionals, researchers and international stakeholders.
Sherley Wang Invited to Participate as an Expert Speaker
As part of the conference programme, Ms. Wang Xueling, an expert from PV Solutions Limited, has been invited to attend the conference and deliver a 15-minute presentation during the main conference and thematic forum sessions on 21 November 2026.
Her invited contribution will focus on topics related to:
Pharmacovigilance
Real-world data applications
Regulatory science
Practical experience and research in pharmaceutical safety and regulation
This invitation reflects the importance of combining practical industry experience with an understanding of China's evolving regulatory environment.
For international pharmaceutical companies operating in China, these areas are increasingly interconnected.
Real-world evidence and post-market safety data are not only scientific resources. They can also support regulatory decision-making, risk management and the continuous assessment of medicines throughout their lifecycle.
Why Real-World Data Matters for Pharmaceutical Companies in China
The pharmaceutical regulatory environment in China is becoming increasingly sophisticated.
While clinical trials remain the foundation for demonstrating the safety and efficacy of medicines, regulators and industry stakeholders are also paying increasing attention to real-world data (RWD) and real-world evidence (RWE).
Real-world data can potentially provide additional information about how medicines are used and perform in routine clinical practice.
Depending on the regulatory context, relevant data may include information from:
Routine clinical practice
Healthcare databases
Patient registries
Electronic medical records
Post-market safety monitoring
Disease registries
Other structured real-world sources
For pharmaceutical companies developing or commercializing products in China, understanding how such data can be generated, evaluated and used within the Chinese regulatory environment is becoming increasingly important.
The Growing Connection Between Pharmacovigilance and Real-World Evidence
Pharmacovigilance is another important area where real-world data can provide valuable insights.
Traditional pharmacovigilance activities focus heavily on the identification, assessment, reporting and monitoring of adverse events and safety signals.
However, broader real-world data sources can potentially contribute additional evidence for:
Safety signal evaluation
Benefit-risk assessment
Risk management
Post-market safety monitoring
Understanding medicine utilization
Identifying safety patterns in broader patient populations
For international MAHs, the challenge is not simply collecting more data.
The critical issue is ensuring that data are relevant, reliable, traceable and appropriately evaluated within the applicable regulatory framework.
This requires an understanding of both scientific methodology and China's regulatory expectations.
China's Regulatory Environment Requires Local Understanding
For international pharmaceutical companies, China's regulatory environment can sometimes appear similar to international frameworks while having important local requirements and implementation practices.
This is particularly relevant to areas such as:
Pharmacovigilance
Clinical research
Real-world evidence
Post-market safety monitoring
Regulatory reporting
Risk management
Data governance
Regulatory inspections
International standards provide an important foundation, but successful implementation in China requires an understanding of how regulatory expectations are applied in the local environment.
This is one of the areas where PV Solutions Limited supports international pharmaceutical companies.
PV Solutions Limited: Connecting International Sponsors with China's Regulatory Environment
PV Solutions Limited supports international pharmaceutical companies, biotechnology companies and other life sciences organizations with their activities in China.
Our expertise includes:
China pharmacovigilance
GVP compliance
GCP audits
Clinical trial inspection readiness
PV system and vendor audits
China regulatory consulting
Pharmacovigilance training
Regulatory intelligence
China market-entry support
Our approach combines international pharmaceutical quality expectations with practical knowledge of China's regulatory environment.
We believe that effective China compliance requires more than translating global procedures into Chinese.
It requires understanding how regulatory requirements are implemented in practice and how international systems can be effectively adapted to the Chinese environment.
Looking Ahead to the Boao Conference
The 5th Boao International Drug and Medical Device Real-World Research Conference provides an opportunity for experts from regulatory authorities, academia and industry to exchange perspectives on the future development of real-world research and regulatory science in China.
PV Solutions Limited is pleased that Sherley Wang has been invited to participate in organizing this important industry event.
We look forward to contributing to the discussion and exchanging practical insights with colleagues from across China's pharmaceutical and life sciences community.
For international pharmaceutical companies, developments in real-world evidence, pharmacovigilance and regulatory science in China are areas worth following closely as the country's regulatory environment continues to evolve.
About PV Solutions Limited
PV Solutions Limited provides China-focused pharmacovigilance, regulatory and GxP consulting services to international pharmaceutical and life sciences companies.
We help global companies navigate China's regulatory environment through practical support in China PV compliance, GVP/GCP audits, clinical trial quality, inspection readiness and regulatory strategy.
For more information about our services, visit PV Solutions Limited.